Needham raises ATRC price target to $64 on BoxX-NoAF trial upside

 

• Needham's Mike Matson lifted PT from $45 to $64 (Buy rating) on Sep 2, directly catalyzing the move.
• BoxX-NoAF trial (ablation + LAA exclusion to prevent post-op AFib) enrolling faster than expected, ahead of schedule.
• Follows Piper Sandler raise to $60 (from $50) on Aug 27 citing new STS quality metric boosting open ablation use.
• Stock hit new 52-week high at ~$52.69; closed at $52.59 (+7.5% from $48.92 prior close) on elevated volume.
• Builds on Q2 2026 beat, raised FY guidance, profitability inflection, and momentum in pain/AFib franchises.
• Analysts highlight large potential TAM expansion if trial succeeds in non-AF cardiac surgery patients.

https://finviz.com/stock?t=ATRC&p=d